Vienna -- In the course of a venture capital transaction, Sanochemia Pharmazeutika AG, listed in the Prime Standard of the Frankfurt Stock Exchange, has acquired a 60% holding in Innsbruck-based AlcaSynn Pharmaceuticals GmbH. Through its stake in this company, founded in 2002 by Prof. Dr. Helmut Schmidhammer and Dr. Johannes Schütz, Sanochemia has secured access to a broad technological base and extensive developmental resources in the fields of pain management and CNS. In cooperation with leading pharmaceutical players, AlcaSynn develops drugs on the basis of synthetic morphinan derivatives with a marked pharmacological profile for the treatment of pain, inflammation, Parkinson’’s and Alzheimer’’s. The company is headed by Dr. Peter Kayatz (CEO) and Dr. Mariana Spetea (CSO) and currently holds a patent portfolio consisting of 13 awarded patents and a further 26 patents pending.
